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Abstract
Background: Extracellular signal-regulated kinase (ERK), one member of the mitogen-activated
protein kinase (MAPK) family, has been suggested to regulate a diverse array of cellular functions,
including cell growth, differentiation, survival, as well as neuronal plasticity. Recent evidence
indicates a role for ERKs in nociceptive processing in both dorsal root ganglion  and spinal cord.
However, little literature has been reported to examine the differential distribution and activation
of ERK isoforms, ERK1 and ERK2, at different levels of pain-related pathways under both normal
and pain states. In the present study, quantitative blot immunolabeling technique was used to
determine the spatial and temporal expression of ERK1 and ERK2, as well as their activated forms,
in the spinal cord, primary somatosensory cortex (SI area of cortex), and hippocampus under
normal, transient pain and persistent pain states.
Results: In naïve rats, we detected regional differences in total expression of ERK1 and ERK2
across different areas. In the spinal cord, ERK1 was expressed more abundantly than ERK2, while
in the SI area of cortex and hippocampus, there was a larger amount of ERK2 than ERK1.
Moreover, phosphorylated ERK2 (pERK2), not phosphorylated ERK1 (pERK1), was normally
expressed with a high level in the SI area and hippocampus, but both pERK1 and pERK2 were barely
detectable in normal spinal cord. Intraplantar saline or bee venom injection, mimicking transient or
persistent pain respectively, can equally initiate an intense and long-lasting activation of ERKs in all
three areas examined. However, isoform-dependent differences existed among these areas, that is,
pERK2 exhibited stronger response than pERK1 in the spinal cord, whereas ERK1 was more
remarkably activated than ERK2 in the S1 area and hippocampus.
Conclusion: Taken these results together, we conclude that: (1) under normal state, while ERK
immunoreactivity is broadly distributed in the rat central nervous system  in general, the relative
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abundance of ERK1 and ERK2 differs greatly among specific regions; (2) under pain state, either
ERK1 or ERK2 can be effectively phosphorylated with a long-term duration by both transient and
persistent pain, but their response patterns differ from each other across distinct regions; (3) The
long-lasting ERKs activation induced by bee venom injection is highly correlated with our previous
behavioral, electrophysiological, morphological and pharmacological observations, lending further
support to the functional importance of ERKs-mediated signaling pathways in the processing of
negative consequences of pain associated with sensory, emotional and cognitive dimensions.
Background
It has been well known that nociceptive information is
transmitted along multiple ascending systems to the brain
[1-3]. Consequently, a diffuse network of brain centers,
each of which contributes to sensory, emotional and cog-
nitive dimensions of pain [4,5], will be activated during
the complex experience of pain [1,6-8]. Among these
brain regions, primary somatosensory cortex (SI area of
cortex), with its anatomical interconnections to nocicep-
tive signal-carrying pathways, has been proposed to be
potently activated following noxious stimulation and to
subserve the somatosensory-discriminative aspects of
pain, such as location and intensity coding of pain [6-10].
In addition, the hippocampus, an integral component of
the 'limbic' system [11,12], may also contribute to the
negative affect and evaluation/cognition of pain experi-
ence [13,14]. It is speculated that nociceptive input may
be integrated in the hippocampus with the context mem-
ory to allow a full appreciation of the meanings and dan-
gers of extraneous pain-producing stimuli. However, so
far, very little is known about the precise cellular and
molecular mechanisms underlying the pain processing in
both SI area and hippocampus.
The generic term of mitogen-activated protein kinases
(MAPKs) is used to denote a family of signal transduction
molecules that transduce a broad range of extracellular
stimuli into diverse intracellular responses by producing
changes in transcriptional modulations of key genes as
well as posttranslational modifications of target proteins
[15-17]. The ERK (extracellular signal-regulated kinase)
members of the MAPK family are originally identified as
the primary effectors of growth factor receptor signaling
and supposed to be involved in the cellular proliferation,
differentiation and survival processes [18-20]. Neverthe-
less, recent evidence suggests a role for ERKs in regulating
neuronal plasticity, such as long-term synaptic potentia-
tion (LTP), long-term depression (LTD) that underlie
learning and memory functions [21-24]. Activated forms
of ERKs act both in the peripheral nociceptor terminal and
the dorsal horn to produce pain hypersensitivity within
an early and short period of their activation by nociceptor
afferent input evoked by acute noxious stimulus, an effect
that is likely due to posttranslational processing [25-27].
Further, peripheral inflammation and nerve injury can
also induce sustained activation of ERKs in both dorsal
root ganglion (DRG) and the second order dorsal horn
neurons (or glial cells), which then lead to enhanced gene
expression and alterations in the neuronal phenotypes,
thus contributing to both inflammatory and neuropathic
pain [28-32]. In spite of these results, few study has been
conducted to determine the possible relationship between
ERKs activation in higher brain regions, such as SI area
and hippocampus, as described above, and multidimen-
sions of pain.
There has been increasing experimental evidence showing
that the clinical pathological pain, charicterized by per-
sistent pain and hyperalgesia, differs greatly from physio-
logical pain, which is acute and transient, warning of
potential or actual tissure or nerve damage [33-36]. There-
fore, the aim of the present series of experiments is to
assess the spatial- and temporal-related changes in phos-
phorylation (activation) and protein expression of ERKs,
mainly ERK1 and ERK2, in the spinal cord dorsal horn, SI
area and hippocampus under both physiological pain
(transient pain) and pathological pain (persistent pain)
states. To attain this goal, we adopted two well-charecter-
ized animal models: (1) subcutaneous (s.c.) injection of
0.9% isotonic saline solution in conscious rats as the
physilogical (transient) pain model, for the injury pro-
duced by the injection itself can be perceived as acute pain
sensation by animals [29]; (2) s.c. injection of a solution
containing the whole bee venom in rats as the pathologi-
cal (persistent) pain model [33,37]. Our previous behav-
ioral studies have demonstrated that s.c. injection of bee
venom into the plantar surface of one hindpaw in con-
scious rats could produce persistent spontaneous nocice-
ption (PSN), heat or mechanical hyperalgesia and also
peripheral inflammation [33,38-40]. Furthermore, our
electrophysiological experiments suggest that the bee
venom model possesses many advantages over the forma-
lin test, another persistent pain model, and may be more
appropriate in evaluation of the mechanisms underlying
clinical pathological pain [41-43]. Besides, we also try to
provide an initial investigation into the differential
regional distribution of ERK isoforms, including their acti-
vated forms, across different areas under normal state, in
hopes of getting a new insight into their isoform-specific
and region-dependent charecteristics in normal expres-BMC Neuroscience 2007, 8:53 http://www.biomedcentral.com/1471-2202/8/53
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sion. Here, we reported region- and state-related differ-
ences in phosphorylation and expression of ERK isoforms
in the rat central nervous system (CNS).
Results
Effects of s.c. injection of saline or bee venom on the 
phosphorylation of ERK1 and ERK2 in the spinal cord
To test the differential expression patterns of ERK1 and
ERK2, as well as their activated forms, in the spinal cord
under normal, transient pain and persistent pain states,
different groups of rats (n = 3/group at each time point)
were injected intraplantarly with 50 μl 0.9% sterile saline
or 50 μl whole bee venom or without any treatment and
homogenates of the spinal cord tissue obtained at various
time points (as described in Materials and methods) were
subsequently probed for phospho-ERK1/2 (pERK1/2) as
well as total ERK1/2 (tERK1/2) using one kind of primary
antibody that could detect these two bands (44 kDa for
ERK1; 42 kDa for ERK2) on the same membrane simulta-
neously. The representative original immunoblotting
bands detected in ipsilateral spinal cord dorsal horn
obtained from three groups of rats were shown in Fig. 1A.
In the normal spinal cord of naïve rats, both pERK1 and
pERK2 were barely detectable at whatever time point we
examined, although there was a considerable amount of
total ERKs constitutively expressed, with ERK1 being more
abundant than ERK2. However, s.c. administration of bee
venom into the plantar surface of one hindpaw, which
could produce a prolonged tonic, monophasic nocicep-
tive response characterized by continuously flinching or
lifting the injected paw for 1–2 h [37,38], significantly ele-
vated the phosphorylation level of both ERK1 and ERK2
in the ipsilateral spinal cord (Fig. 1A, Tables 1 and 2).
Interestingly, saline-treated rats, which exhibited typical
behavioral manifestation of acute and transient pain dur-
ing the process of injection, also displayed a higher level
of both pERK1 and pERK2 compared with control (Fig.
1A, Tables 1 and 2). Fig. 1B illustrates quantitative analy-
sis of the data shown in Fig. 1A. This column graph clearly
demonstrated that both saline-induced transient pain and
bee venom-induced persistent pain can equally elicit the
enhanced expression of activated ERK1 or ERK2 in the
ipsilateral side of the spinal cord dorsal horn for a long
period (about 24–48 h). There were not any significant
differences detected between saline- and bee venom-
treated rats in terms of ERK1 or ERK2 activation (Fig. 1).
In spite of the great differences in basal expression
amounts of total protein between ERK1 and ERK2 in the
normal spinal cord, no significant alterations in tERK1 or
tERK2 level were detected following noxious stimulation,
transient or persistent, when compared to naïve rats,
respectively (data not shown).
From the time course of ERK1 and ERK2 activation in
response to peripheral painful stimulation (Fig. 1B), how-
ever, we could find remarkable differences between the
response properties of ERK2 and ERK1 in terms of both
immunoreactive intensity and duration, with the former
being more susceptible and exhibiting stronger response
than the latter. In fact, significant ERK2 activation was
elicited immediately after injection, and maintained per-
manently until the end of the experiment. This new result
of our experiment supports a piece of indirect evidence to
the proposition that pERK2, but not pERK1, might behave
as a more important intracellular signaling mediator in
the spinal cord in response to peripheral noxious stimula-
tion, although both activated enzymes were rarely pre-
sented in the spinal cord under normal, unstimulated
state.
In the present study, we also assessed the state-dependent,
time-related changes in phosphorylation of both forms of
ERKs in contralateral side of the spinal cord with similar
results obtained (Tables 1 and 2). These results indicate
that ERKs, as important signaling intermediaries, are
abundantly and broadly expressed in the spinal cord nor-
mally (Fig. 1A), enabling them to respond both rapidly
and extensively when those cells receive environmental
noxious stimuli.
Effects of s.c. injection of saline or bee venom on the 
phosphorylation of ERK1 and ERK2 in the S1 area
Despite the reported prevalence and importance of SI area
in pain sensory information processing [6-10], little atten-
tion has been paid to the molecular events occurring in
this cortical area triggered by pain-evoking stimuli. Our
study provided an initial examination about the differen-
tial expression profiles of ERKs in SI area under normal
and different pain states. As shown in Fig. 2A, dramatic
differences were observed in the immunoreactivity of
tERK1 and tERK2 in contralateral S1 area from naïve rats,
with ERK2 expressed more prominently than ERK1. Taken
the results of spinal cord and SI area together, it is not dif-
ficult to find a reversion of ERKs expression mode in these
two areas. With respect to the activated fraction of ERKs,
pERK1 was rarely seen in SI area of naïve rats (Fig. 2A),
however, pERK2 was normally expressed with a high level
in this area at all time points we examined, although little
differences occurred in the exact amounts of pERK2
among some time points.
In an attempt to unmask the state-dependent changes in
the phosphorylation and total expression of ERK1 and
ERK2 and hence illustrate the potential influences of pain-
related behavioral consequence on ERK-mediated intrac-
ellular signaling pathways, we tested the temporal altera-
tions in both pERK1/2 and tERK1/2 after s.c. saline or bee
venom injection. Our immunoblotting results revealed
that pERK1 was induced to express at a highly detectable
level in contralateral SI area following both injection,B
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Table 1: Region- or state-related differences in activation of ERK1 in naïve and pain-experiencing rats.
Spinal cord dorsal horn S1 area of cortex Hippocampus
Naïve Saline Bee venom Naïve Saline Bee venom Naïve Saline Bee venom
5 min
Ipsil 2.61 × 10-3 ± 2.21 × 10-3 0.50 ± 0.11* 0.54 ± 0.20† 2.80 × 10-3 ± 2.80 × 10-3 2.56 ± 1.83 1.08 ± 0.38 0.04 ± 0.03 0.58 ± 0.33 0.93 ± 0.44
Contl 0.02 ± 0.01 0.57 ± 0.31 0.52 ± 0.32 3.32 × 10-3 ± 3.32 × 10-3 0.84 ± 0.30* 0.61 ± 0.24† 0.17 ± 0.13 0.87 ± 0.31 0.81 ± 0.28
15 min
Ipsil 8.49 × 10-4 ± 5.49 × 10-4 0.47 ± 0.08** 0.44 ± 0.09†† 1.63 × 10-3 ± 1.63 × 10-3 0.93 ± 0.30* 0.49 ± 0.23† 0.02 ± 0.01 0.60 ± 0.42 0.55 ± 0.30
Contl 0.02 ± 0.02 0.34 ± 0.12** 0.30 ± 0.07†† 2.61 × 10-4 ± 2.61 × 10-4 0.63 ± 0.28* 0.95 ± 0.40† 0.07 ± 0.04 0.40 ± 0.08* 0.32 ± 0.08†
30 min
Ipsil 2.50 × 10-3 ± 1.98 × 10-3 0.36 ± 0.01*** 0.32 ± 0.05††† 1.14 × 10-3 ± 1.14 × 10-3 0.52 ± 0.16* 0.51 ± 0.20† 4.16 × 10-3 ± 3.43 × 10-3 0.50 ± 0.19* 0.72 ± 0.10†
Contl 0.01 ± 0.01 0.27 ± 0.10 0.25 ± 0.08 4.93 × 10-4 ± 4.93 × 10-4 0.95 ± 0.16* 1.48 ± 0.58† 0.03 ± 0.01 0.38 ± 0.13* 0.75 ± 0.13†
1 h
Ipsil 8.45 × 10-4 ± 7.28 × 10-4 0.64 ± 0.32 0.67 ± 0.26 0 0.65 ± 0.34 0.29 ± 0.07 3.95 × 10-3 ± 3.40 × 10-3 0.64 ± 0.50 0.58 ± 0.42
Contl 7.89 × 10-3 ± 6.95 × 10-3 0.36 ± 0.04** 0.29 ± 0.06†† 0 0.48 ± 0.28** 0.52 ± 0.22†† 0.02 ± 0.02 0.62 ± 0.41 2.23 ± 1.79
2 h
Ipsil 4.71 × 10-4 ± 4.48 × 10-4 0.57 ± 0.10* 0.71 ± 0.22† 2.61 × 10-4 ± 2.61 × 10-4 1.07 ± 0.68 0.56 ± 0.40 0.02 ± 0.02 0.49 ± 0.22 0.66 ± 0.28
Contl 5.99 × 10-3 ± 4.26 × 10-3 0.27 ± 0.07 0.38 ± 0.15† 0 0.57 ± 0.13* 0.55 ± 0.06† 0.03 ± 0.03 0.52 ± 0.18 0.49 ± 0.28
4 h
Ipsil 5.53 × 10-4 ± 3.33 × 10-4 0.44 ± 0.16 0.53 ± 0.21 0 0.65 ± 0.37 0.82 ± 0.52 0.05 ± 0.03 0.37 ± 0.08* 0.59 ± 0.12†
Contl 2.40 × 10-3 ± 1.43 × 10-3 0.35 ± 0.11* 0.34 ± 0.09† 0.07 ± 0.06 1.32 ± 0.48* 1.08 ± 0.16† 0.07 ± 0.05 0.33 ± 0.04 0.52 ± 0.25
6 h
Ipsil 1.13 × 10-3 ± 5.75 × 10-4 0.60 ± 0.22 0.49 ± 0.21 6.79 × 10-4 ± 6.79 × 10-4 0.37 ± 0.09** 0.42 ± 0.03†† 0.04 ± 0.02 1.38 ± 0.83 1.58 ± 0.68
Contl 6.00 × 10-3 ± 5.12 × 10-3 0.49 ± 0.06*** 0.44 ± 0.03††† 0.08 ± 0.08 0.91 ± 0.53 0.60 ± 0.42 0.08 ± 0.06 1.25 ± 0.30* 0.93 ± 0.17†
12 h
Ipsil 1.59 × 10-3 ± 8.16 × 10-4 0.53 ± 0.24* 0.62 ± 0.18† 0 0.53 ± 0.19** 0.54 ± 0.17†† 7.94 × 10-3 ± 5.17 × 10-3 0.75 ± 
0.09***
0.85 ± 
0.16†††
Contl 1.49 × 10-3 ± 6.99 × 10-4 0.45 ± 0.05*** 0.43 ± 0.06††† 4.17 × 10-4 ± 4.17 × 10-4 0.71 ± 0.46 1.02 ± 0.61 0.09 ± 0.09 1.16 ± 0.44* 1.28 ± 0.21†
24 h
Ipsil 7.32 × 10-4 ± 4.13 × 10-4 0.63 ± 0.15* 0.53 ± 0.26† 0 0.62 ± 0.29 1.93 ± 1.52 1.97 × 10-4 ± 1.97 × 10-4 1.28 ± 0.70 0.87 ± 0.40
Contl 1.74 × 10-3 ± 8.96 × 10-4 0.39 ± 0.09** 0.35 ± 0.05†† 5.15 × 10-4 ± 5.15 × 10-4 1.42 ± 0.52* 0.48 ± 0.05† 0.05 ± 0.05 2.02 ± 0.72 0.97 ± 0.22
48 h
Ipsil 5.66 × 10-4 ± 3.37 × 10-4 0.33 ± 0.14 0.38 ± 0.18 1.84 × 10-3 ± 1.84 × 10-3 0.08 ± 0.04 0.16 ± 0.04† 7.45 × 10-3 ± 5.32 × 10-3 0.76 ± 
0.02***
0.50 ± 
0.04†††
Contl 6.04 × 10-3 ± 4.18 × 10-3 0.14 ± 0.02* 0.24 ± 0.05††† 6.85 × 10-4 ± 6.85 × 10-4 0.90 ± 0.83 0.88 ± 0.82 5.59 × 10-3 ± 5.32 × 10-3 0.65 ± 0.16* 0.36 ± 0.08†
Notes: Data are mean ± SEM. for the immunoblotted band intensities of phospho-ERK1 normalized to those of the loading control (total ERK1) obtained from three rats per group. Values from 
ipsilateral (Ipsil.) and contralateral (Contl.) sides of three indicated areas at ten time points are shown. * P < 0.05, ** P < 0.01, *** P < 0.001, saline-treated rats versus naïve control. † P < 0.05, †† P < 
0.01, ††† P < 0.001, bee venom-treated rats versus naïve control.B
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Table 2: Region- or state-related differences in activation of ERK2 in naïve and pain-experiencing rats.
Spinal cord dorsal horn S1 area of cortex Hippocampus
Naïve Saline Bee venom Naïve Saline Bee venom Naïve Saline Bee venom
5 min
Ipsil 0.01 ± 0.01 1.40 ± 0.74* 1.32 ± 0.51† 0.43 ± 0.08 1.03 ± 0.31 0.85 ± 0.18 0.53 ± 0.18 0.61 ± 0.29 0.81 ± 0.13
Contl 0.02 ± 5.12 × 10-3 1.80 ± 0.36** 1.93 ± 0.36†† 0.36 ± 0.05 0.86 ± 0.20 0.79 ± 0.18 0.58 ± 0.18 0.52 ± 0.23 0.77 ± 0.31
15 min
Ipsil 9.51 × 10-3 ± 3.94 × 10-3 1.21 ± 0.40* 0.56 ± 0.15† 0.37 ± 0.10 0.91 ± 0.17 0.64 ± 0.22 0.55 ± 0.21 0.70 ± 0.10 0.67 ± 0.24
Contl 0.01 ± 7.74 × 10-3 1.50 ± 0.31** 1.31 ± 0.28†† 0.37 ± 0.04 0.75 ± 0.20 0.79 ± 0.15 0.49 ± 0.14 0.62 ± 0.18 0.71 ± 0.16
30 min
Ipsil 6.09 × 10-3 ± 1.20 × 10-3 0.93 ± 0.29 1.08 ± 0.40† 0.25 ± 0.10 0.72 ± 0.22 0.59 ± 0.20 0.49 ± 0.19 0.64 ± 0.27 0.79 ± 0.25
Contl 0.03 ± 0.02 1.45 ± 0.30* 1.34 ± 0.32† 0.26 ± 0.06 0.78 ± 0.22** 0.81 ± 0.12†† 0.46 ± 0.17 0.52 ± 0.06 0.69 ± 0.07
1 h
Ipsil 0.01 ± 7.56 × 10-3 1.16 ± 0.46* 1.00 ± 0.30† 0.16 ± 0.08 0.89 ± 0.45 0.91 ± 0.33 0.38 ± 0.17 1.04 ± 0.34 1.22 ± 0.27
Contl 0.06 ± 0.04 1.33 ± 0.20** 1.26 ± 0.20†† 0.15 ± 0.07 0.67 ± 0.27 0.55 ± 0.22 0.44 ± 0.15 1.13 ± 0.40 5.29 ± 4.20
2 h
Ipsil 9.31 × 10-3 ± 2.83 × 10-3 1.35 ± 0.16* 1.21 ± 0.41† 0.22 ± 0.11 0.62 ± 0.15* 0.52 ± 0.04† 0.47 ± 0.19 1.08 ± 0.12* 1.43 ± 0.17††
Contl 0.03 ± 0.02 1.21 ± 0.19* 1.52 ± 0.40†† 0.22 ± 0.10 0.53 ± 0.12* 0.65 ± 0.11† 0.46 ± 0.17 1.19 ± 0.27 1.14 ± 0.31
4 h
Ipsil 0.03 ± 0.03 0.69 ± 0.19* 0.76 ± 0.25† 0.25 ± 0.07 0.73 ± 0.17* 0.77 ± 0.14† 0.61 ± 0.31 0.94 ± 0.28 1.38 ± 0.13
Contl 0.02 ± 9.34 × 10-3 1.11 ± 0.12** 1.40 ± 0.33†† 0.40 ± 0.05 0.93 ± 0.23* 1.10 ± 0.23† 0.55 ± 0.16 0.74 ± 0.05 1.00 ± 0.16
6 h
Ipsil 0.03 ± 0.01 0.67 ± 0.16** 0.63 ± 0.14†† 0.34 ± 0.08 1.19 ± 0.44 0.78 ± 0.13 0.75 ± 0.18 1.38 ± 0.36 1.52 ± 0.27
Contl 0.02 ± 6.72 × 10-3 1.20 ± 0.09*** 1.19 ± 0.14††† 0.32 ± 0.05 1.34 ± 0.63 0.93 ± 0.18 0.67 ± 0.17 1.85 ± 0.57 1.49 ± 0.20
12 h
Ipsil 3.31 × 10-3 ± 1.67 × 10-3 0.75 ± 0.18** 0.73 ± 0.09†† 0.26 ± 0.04 0.82 ± 0.24 0.87 ± 0.20 0.55 ± 0.24 1.15 ± 0.27 1.27 ± 0.14
Contl 0.04 ± 5.41 × 10-3 1.38 ± 0.19** 1.58 ± 0.42†† 0.19 ± 0.05 1.43 ± 0.63 1.64 ± 0.58 0.64 ± 0.17 2.11 ± 0.89 1.63 ± 0.14
24 h
Ipsil 2.81 × 10-3 ± 7.82 × 10-4 0.81 ± 0.16** 0.79 ± 0.15†† 0.11 ± 0.04 1.12 ± 0.59 2.07 ± 1.45 0.44 ± 0.17 1.13 ± 0.40 1.00 ± 0.28
Contl 0.01 ± 7.74 × 10-3 1.58 ± 0.34* 1.06 ± 0.15† 0.09 ± 0.03 1.75 ± 0.47 2.22 ± 1.74 0.61 ± 0.33 2.77 ± 0.93 1.24 ± 0.23
48 h
Ipsil 3.65 × 10-3 ± 2.52 × 10-3 0.74 ± 0.26 0.90 ± 0.34† 0.18 ± 0.06 0.56 ± 0.23 0.48 ± 0.15 0.56 ± 0.27 1.22 ± 0.18 0.76 ± 0.08
Contl 0.08 ± 0.07 1.63 ± 0.21* 2.07 ± 0.66† 0.07 ± 0.01 0.65 ± 0.38 0.73 ± 0.36 0.70 ± 0.38 1.22 ± 0.09 0.86 ± 0.27
Notes: Data are mean ± SEM. for the immunoblotted band intensities of phospho-ERK2 normalized to those of the loading control (total ERK2) obtained from three rats per group. Values from 
ipsilateral (Ipsil.) and contralateral (Contl.) sides of three indicated areas at ten time points are shown. * P < 0.05, ** P < 0.01, *** P < 0.001, saline-treated rats versus naïve control. † P < 0.05, †† P 
< 0.01, ††† P < 0.001, bee venom-treated rats versus naïve control.BMC Neuroscience 2007, 8:53 http://www.biomedcentral.com/1471-2202/8/53
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when compared to the naïve control state (Fig. 2A, Table
1). In clear contrast, pain-induced elevation of pERK2
level was not so much evident as pERK1 when compared
to its corresponding normal state, perhaps due to its high
basal expression level in naïve rats (Fig. 2A, Table 2). A
quantitative analysis of the data (Fig. 2B) further con-
firmed this phenomenon. We can see, from this histo-
gram, that ERK1 was phosphorylated at almost every time
point examined except for 6 h, 12 h, and 48 h, whereas
ERK2 was activated at much less time points. No statisti-
cally significant differences were obtained between two
groups of pain-experiencing rats (Fig. 2). In addition, total
ERKs were unaltered by noxious stimulation given in our
experiment (data not shown).
In addition, the ipsilateral side of SI area was removed
from three groups of rats and SDS-solubilized tissue sam-
ples were subjected to Western blot analysis concomi-
tantly. Almost the same increasing tendency was
observed, but these changes have a more delayed and
restricted temporal profile when compared to the contral-
ateral alterations (Tables 1 and 2).
Temporal changes in phosphorylation and expression of ERKs in ipsilateral spinal cord dorsal horn under three different states Figure 1
Temporal changes in phosphorylation and expression of ERKs in ipsilateral spinal cord dorsal horn under three different states. 
(A) Representative Western blots of spinal cord homogenates from three groups of rats at indicated time points. Left panel in 
each rectangle represents immunodetection of phosphorylated-ERK1/2 (pERK1/2), total ERK1/2 (tERK1/2), and beta-actin, 
which is included as loading control. Right panel in each rectangle shows raw bands corresponding to the left panel. (B) Densi-
tometric quantification from (A) is shown. The pERKs bands were densitized and normalized to tERKs immunoblotted from 
the same membrane to demonstrate the phosphorylation levels of ERKs. Upper panel of B denotes the time course of ERK1 
activation under three assigned states, while lower panel of B illustrates the time-related changes in activation of ERK2. Points 
represent the mean ± S.E.M. from three separate experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, saline-treated rats versus 
naïve control; † P < 0.05, †† P < 0.01, ††† P < 0.001, bee venom-treated rats versus naïve control.BMC Neuroscience 2007, 8:53 http://www.biomedcentral.com/1471-2202/8/53
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Effects of s.c. injection of saline or bee venom on the 
phosphorylation of ERK1 and ERK2 in the hippocampus
Recently, evidence is accumulating that the hippocampal
formation, an integral component of the "limbic" system
[11,12], plays an important role in the cognitive-evalua-
tive and affective-motivational components of pain expe-
rience [13,14]. Nevertheless, the definite role of
phosphorylated ERKs in the hippocampal nociceptive reg-
ulation is not fully characterized yet. In our current study,
rats were treated identically as described above, and then
the time course study for pERK1 and pERK2 under three
assigned status was conducted in the bilateral hippocam-
pus. The results in Fig. 3A were representative of ipsilateral
hippocampal determinations from analyses of three rats
per group per time point. Almost the same type of iso-
form-dependent disparities in ERKs basal expression pro-
file was observed from the raw immunoblotting bands.
That is, paralleled with SI area but contrast to spinal cord
(Fig. 1A and Fig. 2A), tERK2 showed much higher immu-
nolabeling than tERK1, in spite of the fact that this differ-
ence between tERK1 and tERK2 was slightly smaller than
that in SI area of cortex (Fig. 3A). Similarly, pERK2, but
not pERK1, was normally detectable in the hippocampus
from naive rats. It also seemed that pERK2 level in the nor-
mal hippocampus was a bit higher than that in normal SI
area of cortex (Fig. 2A and Fig. 3A). Additionally, s.c. injec-
Temporal changes in phosphorylation and expression of ERKs in contralateral S1 area under three different states Figure 2
Temporal changes in phosphorylation and expression of ERKs in contralateral S1 area under three different states. (A) Repre-
sentative Western blots of neocortical homogenates from three groups of rats at indicated time points. Left panel in each rec-
tangle represents immunodetection of phosphorylated-ERK1/2 (pERK1/2), total ERK1/2 (tERK1/2), and beta-actin, which is 
included as loading control. Right panel in each rectangle shows raw bands corresponding to the left panel. (B) Densitometric 
quantification from (A) is shown. The pERKs bands were densitized and normalized to tERKs immunoblotted from the same 
membrane to demonstrate the phosphorylation levels of ERKs. Upper panel of B denotes the time course of ERK1 activation 
under three assigned states, while lower panel of B illustrates the time-related changes in activation of ERK2. Points represent 
the mean ± S.E.M. from three separate experiments. * P < 0.05, ** P < 0.01, saline-treated rats versus naïve control. † P < 0.05, 
†† P < 0.01, bee venom-treated rats versus naïve control.BMC Neuroscience 2007, 8:53 http://www.biomedcentral.com/1471-2202/8/53
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tion of either saline or bee venom significantly augmented
the activation of ERK1 and ERK2 (Fig. 3A, Tables 1 and 2).
Summarized data shown in Fig. 3B indicated that pERK2
was less changed by noxious stimulation compared with
pERK1. Activation of ERK1 began to increase within 30
min of s.c. injection and remained at a relatively high level
untill the end of the experimental period. However, statis-
tically significant enhancement of pERK2 signal was only
reached at 2 h after intraplantar treatment (Fig. 3B). At
each time point showing enhanced phosphorylation of
ERKs by pain stimulation, no significant differences were
found between the transient pain and the persistent pain
group (Fig. 3). There were no significant changes in total
expression levels of ERK1 or ERK2 in ipsilateral hippoc-
ampus at any time point examined (data not shown).
Western blot analysis was also performed on tissue sam-
ples extracted from contralateral hippocampus of three
groups of rats. The basal expression pattern for ERK1 and
ERK2 was nearly identical to the ipsilateral side (data not
shown). Both saline and bee venom injection resulted in
a significant activation of contralateral hippocampal
ERK1 at the early and late phase of the observation period
(Table 1), whereas no significant changes were detected in
phosphorylation of hippocampal ERK2 on the side con-
tralateral to treatment (Table 2).
Temporal changes in phosphorylation and expression of ERKs in ipsilateral hippocampus under three different states Figure 3
Temporal changes in phosphorylation and expression of ERKs in ipsilateral hippocampus under three different states. (A) Rep-
resentative Western blots of hippocampal homogenates from three groups of rats at indicated time points. Left panel in each 
rectangle represents immunodetection of phosphorylated-ERK1/2 (pERK1/2), total ERK1/2 (tERK1/2), and beta-actin, which is 
included as loading control. Right panel in each rectangle shows raw bands corresponding to the left panel. (B) Densitometric 
quantification from (A) is shown. The pERKs bands were densitized and normalized to tERKs immunoblotted from the same 
membrane to demonstrate the phosphorylation levels of ERKs. Upper panel of B denotes the time course of ERK1 activation 
under three assigned states, while lower panel of B illustrates the time-related changes in activation of ERK2. Points represent 
the mean ± S.E.M. from three separate experiments. * P < 0.05, *** P < 0.001, saline-treated rats versus naïve control. † P < 
0.05, †† P < 0.01, ††† P < 0.001, bee venom-treated rats versus naïve control.BMC Neuroscience 2007, 8:53 http://www.biomedcentral.com/1471-2202/8/53
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Discussion
As a first step toward better understanding about the
potential role of ERKs-mediated signaling pathways in
central neuronal function under different states, we
undertook a detailed analysis of spatiotemporally
dynamic changes in phosphorylation (activation) and
protein expression of two major ERK isoforms in the spi-
nal cord dorsal horn, SI area and hippocampus under nor-
mal, physilogical pain (transient pain) and pathological
pain (persistent pain) states. First, the present study
showed that different ERK isoforms display different
region-related expression profiles in the rat CNS under
normal state. In general, ERKs are abundantly and ubiqui-
tously expressed throughout the rat CNS and are reported
to be present in the cerebral cortex, hippocampus, brain
stem nuclei, cerebellum, thalamus and also in the spinal
cord [44-47]. In our experiment, we detected certain
amounts of ERK1 and ERK2 in normal spinal cord, SI area
of cortex, and hippocampus using Western blot tech-
nique. This distributed expression profile of ERK1 and
ERK2 was consistent with a previous study [44], which
also found a wide distribution of ERK1 and ERK2 in all rat
tissues examined, with the greatest amounts in brain and
spinal cord, using antisera 956 and 837 derived from the
C-terminal peptide predicted by the ERK1 cDNA, respec-
tively. In spite of this global diffusion, regional differences
in the relative abundance of ERK1 and ERK2 have also
been described by previous reports [45,47]. Oritz and his
colleagues found that, while ERK immunoreactivity was
widely distributed in the rat brain, the relative abundance
of ERK1 and ERK2 differed by close to 10-fold among the
regions studied. In fact, they found that the ratio of ERK1
protein to ERK2 protein varied along a rostral-caudal gra-
dient from a lowest of 0.16 in frontal cortex to a highest
of 1.5 in pons/medulla. Moreover, this ratio in the spinal
cord was even higher than that in pons/medulla [47]. Our
blot immunolabeling of ERKs also presented a robust
contrast between ERK1 and ERK2 immunoreactive inten-
sity in the spinal cord dorsal horn, SI area and hippocam-
pus. Interestingly, the relative differences between ERK1
and ERK2 immunoreactivity were quite the same as that
previous study (see the present results). This point is fur-
ther underscored by the Northern blotting data of Boul-
ton et al. [45], who measured levels of ERK1 and ERK2
mRNA in gross subsections of brain. They found, consist-
ent with our immunoblotting data, that ERK2 mRNA did
show a rostral-caudal gradient in expression in different
brain regions. However, what causes this kind of regional
difference and what is the functional significance of this
phenomenon remain largely unclear and await further
elucidation.
The present study also provides information concerning
the differential distribution of activated forms of ERKs,
pERK1 and pERK2, in three examined areas in naïve rats.
Obviously, ERK1 and ERK2 were rarely activated in the
normal spinal cord (Fig. 1), but pERK2 was constitutively
expressed with a high level in the SI area and hippocam-
pus, although pERK1 was still hardly seen in these higher
brain regions at the same time (Figs. 2 and 3). The reasons
for this disparity in the distribution of activated ERK1 and
ERK2 in different areas are not fully understood. A theo-
retically reasonable explanation might be attributed to
different levels of ERK kinase, which catalyzes specifically
the phosphorylation of ERKs at both a threonine and a
neighboring tyrosine residue and activates them [48-50].
Oritz and his colleagues had also investigated the regional
distribution of ERK kinase using blot immunolabeling
procedures and shown that the highest levels of ERK
kinase immunoreactivity were present in nucleus
accumbens, hippocampus, substantia nigra, and caudate/
putamen, with the lowest levels observed in cerebellum
and pons/medulla. They also pointed out that the spinal
cord contained still lower levels of ERK kinase immunore-
activity [47]. Hence, combined with our findings, we
extrapolate from the previous results that it is probably
due to the differential distribution of ERK kinase, MEK1
or MEK2 or other unknown additional members of this
kinase family, that leads to the differential distribution of
pERK1 and pERK2 between spinal and supraspinal level
under normal state observed in the present study. Of
course, this presumption still needs additional verifica-
tion in future studies.
In the present experiments, we also addressed whether or,
if so, to what extent peripherally-induced transient or per-
sistent pain state will influence ERKs phosphorylation sta-
tus and their distribution patterns in the spinal cord and
high-level brain structures. We show here regional selec-
tivity in the phosphorylation of ERK isoforms following
peripheral noxious stimulation, with different sensitivity
and responsibility between ERK1 and ERK2 found in dif-
ferent areas. In the spinal cord dorsal horn, both pERK1
and pERK2 were dramatically elevated in response to tran-
sient or persistent pain stimulation (Fig. 1, Tables 1 and
2). However, the ERK2 enzyme seems to be more sensitive
and exhibit stronger responses than ERK1 enzyme. In SI
area or hippocampus, in contrast, pERK2 was less changed
or changed not so evident and remarkable as pERK1 (Figs.
2 and 3, Tables 1 and 2). These differential activation
properties of ERK1 and ERK2 are in large accordance with
previous reports [51,52]. Several factors may contribute to
this kind of ERKs activation during pain state, such as
glutamatergic receptors (NMDA receptor [53], AMPA
receptor [54], or metabotropic glutamate receptor [55]),
growth factors (nerve growth factor [56] or brain-derived
neurotrophic factor [57]), and so on. However, the rea-
sons for these differential activation patterns of different
isoforms are not clear. We suggest, to some extent, that it
maybe due to the differential activation and regulation ofBMC Neuroscience 2007, 8:53 http://www.biomedcentral.com/1471-2202/8/53
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upstream activators for ERK1 and ERK2 (MEK1 or MEK2,
for example) in different areas under the pain states. A
substantial body of evidence from brain imaging, lesion
and electrophysiological studies indicates that different
components of the nociceptive system may be preferen-
tially involved in different aspects of the complex experi-
ence of pain [4-8]. Combined differential participation of
the spinal cord, SI area, and hippocampus in the multidi-
mensional aspects of pain experience with region- and
isoform-dependent responses of pERK1 and pERK2 to
peripheral noxious stimulation observed in the present
study, we propose a hypothesis that this differential acti-
vation of ERK1 and ERK2 across distinct regions under
pain state might suggest the possibility for a different
function of specific ERK members in the nociceptive
processing and further provide a molecular basis for the
differential involvement of individual components of
nociceptive system in the diverse features of pain.
It has been well documented that pathological pain (per-
sistent or chronic pain) differs greatly from physiological
pain (transient pain) in regards of etiology, symptom,
mechanisms and pathogenesis [33-36]. Therefore, a dif-
ference in the intracellular signaling mechanisms of these
two pain states might also be expected. In the present
study, using ERK as a marker, we sought to address this
issue by virtue of two well-developed animal models: s.c.
injection of 0.9% isotonic saline solution as the transient
pain model, and s.c. injection of whole bee venom solu-
tion as the persistent pain model. In our pilot experi-
ments, we did not observe marked paw flinching (or
lifting) responses behaviorally (paralleled with previous
observations [37,58]), nor did we find long-lasting
increase in spontaneous spike discharges of spinal cord
dorsal horn neurons electrophysiologically following
intraplantar saline injection in conscious rats (data not
shown). However, saline-treated rats did exhibit typical
behavioral manifestation of acute, localized, transient
pain during the process of injection, such as slight with-
drawal of the hindpaw, the desire to escape, and even
vocalization some times. All of these observations, there-
fore, led us to the conclusion that s.c. injection of isotonic
0.9% saline can indeed elicit transient, but not persistent
pain in conscious rats. Somewhat unexpectedly, our
present immunoblotting results did not reveal any signif-
icant differences in the activation of ERK1 or ERK2
between saline- and bee venom-treated rats with regards
to either response intensity or duration. This result is in
contrast to a previous study [59], which showed a signifi-
cant increase of pERK in the spinal cord and hippocampus
following intrathecal (i.t.) substance P injection, another
well-characterized pain model [60], but not after i.t. saline
treatment. This discrepancy between their results and ours
may be ascribed to many differences in experimental
design and procedure, such as the animal species used (rat
vs. mouse) or the route of drug administration (s.c. vs. i.t.)
or the observation period (long-term vs. short term). Con-
sistent with our present findings, Galan et al. [29] has also
reported that intraplantar saline injection resulted in a
2.5-fold activation of spinal ERK in juvenile rats, but this
activation only persisted until 45 min after intraplantar
injection. Our results in the current study extend their
findings by showing an even longer activation of ERKs to
24–48 h after intraplantar treatment with saline in both
spinal cord and higher-level brain structures. Another new
finding of this study, in comparison with that previous
report, was that we observed differential response patterns
between different ERK isoforms in response to peripher-
ally-evoked pain state. The precise mechanisms for this
saline-induced phosphorylation of ERKs are not clear.
However, since several intracellular kinase cascades con-
verge on MAPK activation [23,61-63], it is not unreasona-
ble to speculate that ERK, as a member of highly
conserved and ubiquitously distributed MAPK family [15-
17], might serve as a constitutive integrator of multiple
inputs from extracellular environment, so that even tran-
sient pain could immediately activate it and hence trigger
a series of adaptive changes in the intracellular signal
transduction.
Another most important point to be noted is that the iso-
tonic and sterile saline solution we used in the present
study has a low PH value (PH = 6.4). There is ample evi-
dence demonstrating that acidic saline treatment, intra-
muscular injection or topical application, can produce a
bilateral, long-term mechanical hyperalgesia in rats
[64,65]. Thus, the present results could not exclude the
possibility that the long-lasting enhanced activation of
ERKs by saline-induced transient pain is partially attribut-
able to the effects exerted by its low PH nature. Besides,
one of the more interesting and striking findings from the
present study is that unilateral injection of saline or bee
venom solution elicited bilateral phosphorylation of
ERKs in three areas examined, although the effects of the
other side were not so much evident and usually had a
more delayed and restricted temporal profile (see Tables 1
and 2). More recently, different experiments employing
multidisciplinary approaches in animals and humans
have clearly demonstrated that the bee venom treatment
could produce not only persistent spontaneous nocicep-
tion associated with long-term primary mechanical and
heat hyperalgesia at injection site, but also heat hyperalge-
sia identified in the surrounding secondary area and even
the remote contralateral non-injection limb, the so-called
"mirror-image" thermal hyperalgesia [33,38-40,66-69].
Our observations concerning the bilateral activation of
ERKs following bee venom injection were highly corre-
lated with the above reports. According to our previous
investigations, it is further suggested that a communica-
tion mediated by commissural interneurons in the ratBMC Neuroscience 2007, 8:53 http://www.biomedcentral.com/1471-2202/8/53
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CNS might contribute to the above-mentioned bilateral
ERKs activation as well as mirror-image hyperalgesia iden-
tified in the bee venom model [66,70]. With respect to the
saline-induced bilateral ERKs activation, we have reason
to believe that the low PH nature of the saline solution
might be responsible, at least in part, for this phenome-
non [64,65].
The present study also tested the time course of this nox-
ious stimulation-induced ERKs activation, from 5 min to
48 h. The temporal pattern (lasting 24–48 h) of bee
venom-induced spinal or cortical ERKs activation differed
substantially from the transient (<2 h) ERKs activation
reported after intradermal injection of capsaicin or forma-
lin [26,27,51], but is mostly in accordance with the ERKs
activation induced by intraplantar Complete Freund's
adjuvant (CFA) administration [30]. This long-term acti-
vation of ERKs correlates well with our previous behavio-
ral, morphological and electrophysiological studies
[33,38-43,71]. On the basis of these findings, therefore,
we suppose that ERKs activation in the early phase of bee
venom-evoked inflammation, from 5 min to 1 h, might
be involved in the development or maintenance of per-
sistent spontaneous nociception (lasting 1–2 h); while the
later phase of ERKs activation, from 2 h to 48 h, might
participate in the bee venom-produced thermal or
mechanical hyperalgesia (lasting 24–72 h). This point is
further confirmed by our previous pharmacological study
[72], in which i.t. administration of U0126, a widely used
specific MEK inhibitor [73], significantly blocked the
induction and maintenance of melittin-induced persist-
ent spontaneous nociception and heat hyperalgesia, while
the same treatment only significantly suppressed the
induction, but not maintenance, of melittin-induced
mechanical hypersensitivity. Our recent studies have
demonstrated that melittin, which composes over 50% of
the whole bee venom [74], is the major algogenic compo-
nent for the bee venom-produced long-term changes in
peripheral and central neural plasticity as well as abnor-
mal pain behaviors [39,75], Therefore, these spinal
pharmcological results and our present blot immunolabe-
ling data add to an incrementing body of evidence for the
functional involvement of phosphorylated ERKs in medi-
ating nociceptive signal transmission and sensitization in
the bee venom model.
Conclusion
In the present study, we provided a new line of evidence
showing region- or state-related differences in expression
and activation between ERK1 and ERK2 along the pain-
related CNS pathways in rats. Under normal state, the rel-
ative abundance of constitutive ERK1 and ERK2 differs
greatly among specific regions in the rat CNS, while under
pain state, both ERK1 and ERK2 can be effectively phos-
phorylated with a long-term duration by both transient
and persistent pain, but with their response patterns being
different from each other across distinct regions as well.
The long-lasting ERKs activation induced by peripheral
bee venom injection is highly correlated with our previ-
ous behavioral, electrophysiological, morphological and
pharmacological observations, lending further support to
the functional importance of ERKs-mediated signaling
pathways in the processing of negative consequence of
pain associated with sensory, emotional and cognitive
dimensions.
Methods
Animal model
All experiments were carried out on male Sprague-Dawley
rats (Animal Center of Capital Medical University, Beijing,
PR China) weighing from 220 to 250 g. The animals were
housed five per cage with food and water available ad libi-
tum, and kept under controlled conditions of temperature
(20–25°C) and light (12 h light/12 h dark cycle). This
animal protocol was approved by University Institutional
Animal Care and Use Committee of Capital Medical Uni-
versity and was consistent with the ethical guidelines of
the International Association for the Study of Pain for
pain research in conscious animals [76]. All efforts were
made to minimize animal suffering and to reduce the
number of animals used. The rats were randomly divided
into three groups: (1) rats without any treatment as naïve
control (normal state, n = 3/time point); (2) rats with s.c.
injection of 0.9% sterile, isotonic saline solution (PH =
6.4) as the physiological pain model (transient pain state,
n = 3/time point); (3) rats with s.c. injection of whole bee
venom solution as the pathological pain model (persist-
ent pain state, n = 3/time point).
Administration of drugs
Bee venom was lyophilized whole venom of Apis mellifera
(Sigma, St. Louis, MO) dissolved in 0.9% sterile saline. A
volume of 50 μl saline containing 0.1 mg bee venom was
used during the whole experiment, because it was shown
that 0.1–0.2 mg/50 μl was the optimal dose to produce a
prolonged pain-related behavioral response [37]. Another
parallel group of rats received an equal volume of 0.9%
isotonic, sterile saline solution (PH = 6.4, Sodium Chlo-
ride Injection for medical use, purchased from Yangzhou
Zhongbao Pharmaceutical Co., Ltd.). Subcutaneous injec-
tion of bee venom or saline was administered into the
posterior plantar surface of the right hind paw of rats as
reported previously [38]. Briefly, a 26-gauge 5/8 inch nee-
dle connected to a 0.1 ml syringe was used and the solu-
tion was delivered as rapidly as possible while the animal
was immobilized.
Tissue processing and sample preparation
In order to examine the spatial and temporal patterns of
ERK1/2 phosphorylation and expression, all three groupsBMC Neuroscience 2007, 8:53 http://www.biomedcentral.com/1471-2202/8/53
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of rats were anesthetized with intraperitoneal injection of
sodium pentobarbital (50 mg/kg, i.p.) and decapitated at
various time points (5 min, 15 min, 30 min, 1 h, 2 h, 4 h,
6 h, 24 h, 48 h) after the injection. The bilateral SI area
and hippocampus tissue were extracted sequentially
according to the atlas of Paxinos and Watson [77] and
then placed in an ice-cooled glass dish. Subsequently, the
whole spinal cord of each rat was removed by pressure
expulsion with saline into the same dish. The lumborsac-
ral enlargement was identified as required, excised into
two sections, ipsilateral and contralateral to the injected
side, from which the dorsal horn part was eventually dis-
sected. At last, all of these sections were labeled and snap-
frozen in liquid nitrogen (-80°C) until further treatment.
The sectioned tissues were homogenized at 4°C in
homogenizing buffer [50 mM Tris-Cl, pH 7.5, containing
2 mM dithiothreitol, 2 mM EDTA, 2 mM EGTA, 50 μM (2-
aminoethyl)-benzenesulfonylfluoride hydrochloride, 5
mg/ml each of leupeptin, aprotinin, pepstatin A, and chy-
mostatin, 50 mM KF, 50 nM okadaic acid, 5 mM sodium
pyrophosphate, and 2% SDS] and sonicated to dissolve
the tissue completely. Then, the protein amounts of sam-
ples were determined by BCA kit (Pierce, USA).
SDS-PAGE and immunoblotting
The levels of phosphorylation and protein expression of
ERK1/2 were determined using Western blot technique as
described previously [78]. Briefly, 30 μg of protein from
the tissue homogenates of each sample was loaded onto
10% SDS-PAGE gel. Then, the protein was separated by
ice-cooled electrophoresis, after which separated protein
was electrophoretically transferred onto nitrocellulose
membranes (Schleicher & Schuell, USA) at 4°C. The
transferred membrane was firstly blocked by incubating
in blocking buffer (10% non fat dry milk in Tris-buffered
saline containing 0.05% Tween 20) for 1 h at room tem-
perature (RT).
After washing 3 × 10 min in TTBS (20 mM Tris-Cl, pH 7.5,
containing 0.15 M NaCl and 0.05% Tween 20), the mem-
branes were incubated with following primary antibodies
at a 1:1000 dilution for 4 h at RT: rabbit anti-mouse phos-
pho-p44/p42 ERK1/2 pAb (Cell Signaling Technology,
USA); rabbit anti-mouse pan-p44/p42 ERK1/2 pAb (Cell
Signaling Technology, USA); or mouse anti-human beta-
actin mAb (Sigma, USA). The membranes were exten-
sively washed three times with TTBS and then incubated
with horseradish peroxidase-conjugated goat anti-rabbit
or goat anti-mouse secondary antibody (Bio-Rad, USA) at
a 1:3000 dilution for 2 h at RT. After washing another
three times with TTBS, immunoblotting signals were visu-
alized by treatment with ECL reagent (PerkinElmer Life
Sciences, USA) and exposure to film.
Quantitative analysis and data presentation
Densitometric quantification of immunoreactive bands
was performed with GelDoc-2000 Imagine System (Bio-
Rad, USA). Since the primary antibodies we used in the
present experiment detected both ERK1 (p44) and ERK2
(p42), which have different molecular weights, two bands
(44 kDa and 42 kDa) were visualized at last. So both of
the bands were captured with the image analysis system
and the intensity of each band was quantified separately.
The value of the relative optical density of each band cor-
responding to phospho-ERK1/2 was normalized to the
value of total-ERK1/2 to demonstrate the phosphoryla-
tion level; the relative density of each band corresponding
to total-ERK1/2 was normalized to the value of beta-actin
band to illustrate the protein expression level. All pre-
sented data were expressed as means ± S.E.M. from three
independent experiments.
Statistical analysis
Statistical analysis was conducted by one way analysis of
variance (ANOVA) followed by individual post-hoc mul-
tiple comparisons (Fisher's PLSD test). A statistical differ-
ence was accepted as significant at P < 0.05.
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